

For Public Release
NZX Limited
Wellington

19 August 2022

Cannasouth Rights Issue Offer Document

Cannasouth Limited (NZX:CBD) announced its intention to launch a 1 for 10 pro-rata renounceable rights issue to raise up to circa \$4.1 million ("Rights Offer") on Friday 12th August 2022.

The Rights to acquire new shares in CBD will be quoted on the NZX Main Board from today under ticker code "CBDRA".

The Rights Issue Offer Document is attached with this market announcement. The Offer Document, together with a Letter of Entitlement and Acceptance Form, will be sent to all eligible shareholders on Tuesday, 23 August 2022.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO / Company Secretary
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products will be produced under GxP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd, and Midwest Pharmaceuticals NZ Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>